Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: prostate cancer vaccine, intradermal vaccination, castration-resistant prostate cancer, metastatic prostate cancer, PSA, prostate stem cell antigen, prostate-specific membrane antigen, STEAP1, vaccine safety, immune response, antigen-specific T cells, NK cell activation, B cells, urinary retention, dose escalation, immunotherapy, tetramer analysis, ELISPOT
Open Access status: closed
OpenAlex ID: W2242153643
